JAZZ: Jazz Pharmaceuticals Plc
About
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Current Value
$121.851 Year Return
Current Value
$121.851 Year Return
Key Details
Market Cap
$7.35B
P/E Ratio
17.51
1Y Stock Return
0.11%
1Y Revenue Growth
5.23%
Dividend Yield
0.00%
Price to Book
1.8
Strategies that include JAZZ
Stock's related to JAZZ
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VTRS | 44.15% | $15.76B | +36.36% | 3.63% |
| TRS | 40.62% | $1.08B | +2.66% | 0.60% |
| GRAL | 39.95% | $629.34M | +10.18% | 0.00% |
| CLDT | 38.71% | $449.99M | -9.89% | 3.00% |
| ALEX | 36.38% | $1.42B | +11.81% | 4.53% |
| PETS | 36.27% | $94.43M | -40.57% | 0.00% |
| EVTC | 35.99% | $2.29B | -5.76% | 0.56% |
| SRI | 35.54% | $194.92M | -58.44% | 0.00% |
| CSTL | 35.44% | $879.43M | +57.39% | 0.00% |
| REGN | 35.12% | $83.77B | -7.41% | 0.00% |
| TTEC | 35.06% | $249.62M | -73.45% | 1.14% |
| GOLF | 34.97% | $4.47B | +25.01% | 0.87% |
| KAR | 34.51% | $2.15B | +34.13% | 0.00% |
| DAVA | 34.38% | $1.26B | -56.07% | 0.00% |
| UHT | 34.15% | $579.05M | -2.88% | 6.91% |
| CWAN | 34.07% | $7.10B | +62.21% | 0.00% |
| ADTN | 33.94% | $686.00M | +41.80% | 0.00% |
| BY | 33.92% | $1.39B | +46.23% | 1.14% |
| CSV | 33.88% | $616.08M | +72.14% | 1.12% |
| OLO | 33.85% | $1.20B | +25.13% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DXCM | 0.02% | $30.98B | -32.92% | 0.00% |
| BYRN | -0.04% | $412.04M | +204.99% | 0.00% |
| TPST | -0.07% | $41.52M | -71.85% | 0.00% |
| PCVX | 0.18% | $11.42B | +69.07% | 0.00% |
| WDAY | 0.29% | $66.89B | -6.60% | 0.00% |
| EDR | 0.34% | $9.39B | +24.76% | 0.79% |
| ALAR | 0.35% | $87.68M | +155.94% | 0.00% |
| FLXS | 0.37% | $316.23M | +224.53% | 1.02% |
| CDNS | -0.40% | $85.10B | +17.76% | 0.00% |
| MSDL | 0.43% | $1.89B | +4.09% | 7.02% |
| PDD | -0.43% | $137.46B | -30.70% | 0.00% |
| CRM | 0.43% | $316.45B | +32.06% | 0.37% |
| MNR | 0.47% | $1.59B | -13.83% | 20.59% |
| LRCX | 0.47% | $101.02B | +10.57% | 10.62% |
| MCK | 0.52% | $78.87B | +35.27% | 0.43% |
| FICO | -0.53% | $56.78B | +107.77% | 0.00% |
| AMD | -0.57% | $230.54B | +19.81% | 0.00% |
| PSLV | 0.65% | - | - | 0.00% |
| SPOT | -0.65% | $94.02B | +147.35% | 0.00% |
| GNK | 0.66% | $663.60M | -0.83% | 10.03% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MELI | -16.38% | $98.98B | +22.06% | 0.00% |
| PSTG | -15.28% | $17.38B | +61.26% | 0.00% |
| KODK | -14.04% | $580.49M | +92.53% | 0.00% |
| GDRX | -13.24% | $1.89B | -23.85% | 0.00% |
| SOC | -12.39% | $1.91B | +72.84% | 0.00% |
| HUSA | -12.04% | $17.54M | -25.14% | 0.00% |
| PRPH | -10.83% | $18.76M | -83.80% | 0.00% |
| VERX | -10.27% | $8.52B | +92.06% | 0.00% |
| TDG | -10.24% | $70.88B | +37.57% | 0.00% |
| LILAK | -9.83% | $1.38B | -3.03% | 0.00% |
| LILA | -9.60% | $1.39B | -1.39% | 0.00% |
| TCTM | -9.42% | $7.90M | -31.31% | 0.00% |
| RBLX | -8.38% | $34.23B | +26.51% | 0.00% |
| QNRX | -8.34% | $3.22M | -86.64% | 0.00% |
| SMCI | -8.28% | $24.59B | +57.69% | 0.00% |
| SUN | -8.15% | $7.71B | +6.52% | 6.17% |
| UEC | -7.94% | $3.33B | +20.00% | 0.00% |
| BAK | -7.18% | $883.35M | -29.67% | 0.00% |
| OCX | -6.95% | $41.25M | -38.44% | 0.00% |
| MNDY | -6.89% | $13.70B | +50.82% | 0.00% |
ETF's related to JAZZ
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| AGZ | 0.11% | $702.15M | 0.2% |
| USCI | -0.12% | $188.19M | 1.07% |
| FBY | 0.31% | $142.09M | 0.99% |
| GSY | 0.39% | $2.35B | 0.23% |
| YEAR | -0.40% | $1.14B | 0.25% |
| XONE | -0.44% | $550.19M | 0.03% |
| FTSM | -0.52% | $6.04B | 0.45% |
| AMDY | 0.64% | $148.59M | 0.99% |
| SPTS | 0.71% | $5.58B | 0.03% |
| CPER | -0.72% | $156.19M | 0.97% |
| XHLF | 0.85% | $900.10M | 0.03% |
| AGGH | -0.95% | $255.84M | 0.29% |
| KCCA | -1.11% | $219.07M | 0.87% |
| TBIL | -1.21% | $4.42B | 0.15% |
| VGSH | 1.37% | $19.36B | 0.04% |
| URA | -1.37% | $3.83B | 0.69% |
| MINT | -1.39% | $11.69B | 0.35% |
| XBIL | 1.44% | $633.44M | 0.15% |
| UTWO | 1.52% | $443.59M | 0.15% |
| JUCY | 1.67% | $325.86M | 0.6% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -14.32% | $195.31M | 0.85% |
| CORN | -14.21% | $59.94M | 0.2% |
| TPMN | -13.09% | $40.42M | 0.65% |
| BTAL | -12.87% | $365.42M | 1.43% |
| SOYB | -11.20% | $27.06M | 0.22% |
| IVOL | -10.84% | $504.55M | 1.02% |
| DBO | -7.91% | $218.47M | 0.77% |
| GSG | -7.65% | $932.06M | 0.75% |
| BIL | -7.60% | $34.29B | 0.1356% |
| BCI | -7.54% | $1.21B | 0.26% |
| CMDY | -7.52% | $284.26M | 0.28% |
| UUP | -7.40% | $376.91M | 0.77% |
| TDTT | -7.37% | $1.92B | 0.18% |
| COMT | -7.20% | $839.86M | 0.48% |
| PDBC | -7.10% | $4.39B | 0.59% |
| DBE | -7.02% | $50.22M | 0.77% |
| JBBB | -7.01% | $1.35B | 0.49% |
| WEAT | -6.95% | $119.27M | 0.28% |
| TAIL | -6.91% | $68.19M | 0.59% |
| EQLS | -6.89% | $8.93M | 1% |
News
Yahoo
The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SeekingAlpha
Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with multiple catalysts ahead.
Yahoo
We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In this article, we are going to take a look at where Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands against other most undervalued pot stocks to buy according to analysts. A decade ago, the cannabis industry was in full swing as […]
SeekingAlpha
US equities collectively finished the third quarter of 2024 with record-high performance. Click here to read the full commentary.
Yahoo
ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SeekingAlpha
Avadel Pharmaceuticals' Lumryz competes with Xyrem but faces major hurdles. Read why AVDL stock is risky, despite recent legal victories and FDA approval.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.